Selected References:

  • Mariette X, et al. 2017. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study., Ann Rheum Dis; 0:1–6. doi:10.1136/annrheumdis-2017-212196
  • Clowse, ME, et al. 2018. Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from a Pharmacovigilance Safety Database. Arthritis Rheumatol. Accepted Author Manuscript. doi:10.1002/art.40508
  • Clowse MEB, et al. 2017. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis; 76:1890–1896.
  • Cimzia Prescribing Information. Available online at https://www.cimzia.com/sites/default/files/docs/CIMZIA_Current_COL_03-2018_effective_21_March_2018.pdf Accessed 16 April 2018.
  • Förger F, et al. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine. 83:341–343.
  • Habal FM and Huang VW. 2012. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 35(5):501-15.
  • Khan N, et al. 2014. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf; 13(12):1699-708.
  • Mahadevan U, et al. 2011. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: pregnancy and pediatrics. Am J Gastroenterol. 106(2):214-23
  • Mahadevan U, et al. 2012. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 142(Suppl 1):S149. Abstract 865.
  • Mahadevan, U., et al. 2017. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients with Inflammatory Bowel Disease. Gastroenterology 152(2):451-462.e452.
  • Oussalah A, et al. 2009. Certolizumab use in pregnancy. Gut. 58(4):608.
  • Wakefield I, et al. 2011. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNF alpha PEGylated Fab’ monoclonal antibody. Toxicol Sci 122(1):170-6.
  • Weber-Schoendorfer C; network of French pharmacovigilance centres, et al. 2015. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol; 80(4):727-39.
  • Wolf D and Mahadevan U. 2010. Certolizumab use in pregnancy: low levels detected in cord blood. Arthritis Rheum [abstract] 62Suppl10:718.